- A new pill, daraxonrasib, developed by Revolution Medicines, could significantly extend the lives of patients with late-stage pancreatic cancer.
- Results from a 500-person Phase 3 trial showed that patients taking daraxonrasib had a 60% reduced risk of death compared to those on chemotherapy.
- Patients treated with daraxonrasib lived an average of 13.2 months, nearly double the 6.7 months for those receiving only chemotherapy.
- The drug works by blocking the mutated RAS gene, which is a key factor in various cancers, offering a more targeted treatment approach.
- Revolution Medicines intends to submit the trial data to the U.S. Food and Drug Administration for approval, with the agency already expediting promising medicines.
IN FULL
